beatson institute for cancer research
beatson institute for cancer research Company Information
Company Number
SC084170
Next Accounts
Dec 2025
Shareholders
-
Group Structure
View All
Industry
Other research and experimental development on natural sciences and engineering
Registered Address
garscube estate, switchback road, bearsden, glasgow, G61 1BD
Website
http://beatson.gla.ac.ukbeatson institute for cancer research Estimated Valuation
Pomanda estimates the enterprise value of BEATSON INSTITUTE FOR CANCER RESEARCH at £47.3m based on a Turnover of £25.7m and 1.84x industry multiple (adjusted for size and gross margin).
beatson institute for cancer research Estimated Valuation
Pomanda estimates the enterprise value of BEATSON INSTITUTE FOR CANCER RESEARCH at £5.6m based on an EBITDA of £647.4k and a 8.7x industry multiple (adjusted for size and gross margin).
beatson institute for cancer research Estimated Valuation
Pomanda estimates the enterprise value of BEATSON INSTITUTE FOR CANCER RESEARCH at £49m based on Net Assets of £25.4m and 1.93x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Beatson Institute For Cancer Research Overview
Beatson Institute For Cancer Research is a live company located in bearsden, G61 1BD with a Companies House number of SC084170. It operates in the other research and experimental development on natural sciences and engineering sector, SIC Code 72190. Founded in August 1983, it's largest shareholder is unknown. Beatson Institute For Cancer Research is a mature, large sized company, Pomanda has estimated its turnover at £25.7m with declining growth in recent years.
Upgrade for unlimited company reports & a free credit check
Beatson Institute For Cancer Research Health Check
Pomanda's financial health check has awarded Beatson Institute For Cancer Research a 4.5 rating. We use a traffic light system to show it exceeds the industry average on 6 measures and has 3 areas for improvement. Company Health Check FAQs
6 Strong
2 Regular
3 Weak
Size
annual sales of £25.7m, make it larger than the average company (£4.4m)
£25.7m - Beatson Institute For Cancer Research
£4.4m - Industry AVG
Growth
3 year (CAGR) sales growth of -8%, show it is growing at a slower rate (7%)
-8% - Beatson Institute For Cancer Research
7% - Industry AVG
Production
with a gross margin of 49.9%, this company has a comparable cost of product (49.9%)
49.9% - Beatson Institute For Cancer Research
49.9% - Industry AVG
Profitability
an operating margin of -4.4% make it less profitable than the average company (3.3%)
-4.4% - Beatson Institute For Cancer Research
3.3% - Industry AVG
Employees
with 306 employees, this is above the industry average (44)
306 - Beatson Institute For Cancer Research
44 - Industry AVG
Pay Structure
on an average salary of £49.5k, the company has an equivalent pay structure (£60.7k)
£49.5k - Beatson Institute For Cancer Research
£60.7k - Industry AVG
Efficiency
resulting in sales per employee of £84.1k, this is less efficient (£120.9k)
£84.1k - Beatson Institute For Cancer Research
£120.9k - Industry AVG
Debtor Days
it gets paid by customers after 37 days, this is earlier than average (52 days)
37 days - Beatson Institute For Cancer Research
52 days - Industry AVG
Creditor Days
its suppliers are paid after 55 days, this is slower than average (43 days)
55 days - Beatson Institute For Cancer Research
43 days - Industry AVG
Stock Days
There is insufficient data available for this Key Performance Indicator!
- - Beatson Institute For Cancer Research
- - Industry AVG
Cash Balance
has cash to cover current liabilities for 276 weeks, this is more cash available to meet short term requirements (39 weeks)
276 weeks - Beatson Institute For Cancer Research
39 weeks - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 10.4%, this is a lower level of debt than the average (38%)
10.4% - Beatson Institute For Cancer Research
38% - Industry AVG
BEATSON INSTITUTE FOR CANCER RESEARCH financials
Beatson Institute For Cancer Research's latest turnover from March 2024 is £25.7 million and the company has net assets of £25.4 million. According to their latest financial statements, Beatson Institute For Cancer Research has 306 employees and maintains cash reserves of £15.6 million as reported in the balance sheet.
Data source: Companies House, Pomanda Estimates
| Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Mar 2015 | Mar 2014 | Mar 2013 | Mar 2012 | Mar 2011 | Mar 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | 25,724,000 | 24,354,000 | 27,405,000 | 33,225,000 | 39,346,000 | 29,172,000 | 25,933,000 | 23,468,000 | 27,340,000 | 20,795,000 | 21,005,000 | 20,290,000 | 20,844,000 | 20,553,000 | 17,987,000 |
| Other Income Or Grants | |||||||||||||||
| Cost Of Sales | |||||||||||||||
| Gross Profit | |||||||||||||||
| Admin Expenses | |||||||||||||||
| Operating Profit | |||||||||||||||
| Interest Payable | |||||||||||||||
| Interest Receivable | |||||||||||||||
| Pre-Tax Profit | -205,000 | -3,213,000 | -2,489,000 | 3,022,000 | 11,985,000 | -3,427,000 | -1,120,000 | 3,439,000 | -1,692,000 | -264,000 | -755,000 | 1,837,000 | 3,884,000 | 2,475,000 | |
| Tax | -549,000 | ||||||||||||||
| Profit After Tax | -205,000 | -3,213,000 | -2,489,000 | 3,022,000 | 11,985,000 | -3,427,000 | -1,120,000 | 2,890,000 | -1,692,000 | -264,000 | -755,000 | 1,837,000 | 3,884,000 | 2,475,000 | |
| Dividends Paid | |||||||||||||||
| Retained Profit | -205,000 | -3,213,000 | -2,489,000 | 3,022,000 | 11,985,000 | -3,427,000 | -1,120,000 | 2,890,000 | -1,692,000 | -264,000 | -755,000 | 1,837,000 | 3,884,000 | 2,475,000 | |
| Employee Costs | 15,134,000 | 14,014,000 | 14,576,000 | 14,999,000 | 14,850,000 | 13,431,000 | 12,064,000 | 11,607,000 | 11,256,000 | 10,435,000 | 10,214,000 | 9,889,000 | 9,178,000 | 8,211,000 | 7,785,000 |
| Number Of Employees | 306 | 279 | 313 | 321 | 319 | 304 | 270 | 261 | 266 | 253 | 248 | 244 | 230 | 208 | 196 |
| EBITDA* |
* Earnings Before Interest, Tax, Depreciation and Amortisation
| Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Mar 2015 | Mar 2014 | Mar 2013 | Mar 2012 | Mar 2011 | Mar 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tangible Assets | 8,034,000 | 7,884,000 | 9,465,000 | 11,208,000 | 12,389,000 | 13,505,000 | 13,330,000 | 12,867,000 | 13,867,000 | 14,124,000 | 15,091,000 | 15,403,000 | 16,665,000 | 13,956,000 | 9,743,000 |
| Intangible Assets | 48,000 | 42,000 | 41,000 | 28,000 | 85,000 | 164,000 | 237,000 | ||||||||
| Investments & Other | |||||||||||||||
| Debtors (Due After 1 year) | |||||||||||||||
| Total Fixed Assets | 8,034,000 | 7,932,000 | 9,507,000 | 11,249,000 | 12,417,000 | 13,590,000 | 13,494,000 | 13,104,000 | 13,867,000 | 14,124,000 | 15,091,000 | 15,403,000 | 16,665,000 | 13,956,000 | 9,743,000 |
| Stock & work in progress | |||||||||||||||
| Trade Debtors | 2,662,000 | 3,396,000 | 1,795,000 | 2,038,000 | 1,656,000 | 1,590,000 | 1,424,000 | 1,098,000 | 1,839,000 | 565,000 | 572,000 | 260,000 | 405,000 | 483,000 | |
| Group Debtors | 1,001,000 | 977,000 | 1,598,000 | 1,458,000 | 979,000 | 2,024,000 | 1,016,000 | 154,000 | 736,000 | 314,000 | 611,000 | 79,000 | 97,000 | 297,000 | 797,000 |
| Misc Debtors | 1,067,000 | 1,201,000 | 920,000 | 1,032,000 | 1,377,000 | 1,742,000 | 1,708,000 | 1,735,000 | 1,629,000 | 2,169,000 | 357,000 | 389,000 | 458,000 | 375,000 | 332,000 |
| Cash | 15,614,000 | 19,419,000 | 23,071,000 | 23,040,000 | 19,687,000 | 6,889,000 | 7,534,000 | 8,728,000 | 8,159,000 | 6,984,000 | 6,475,000 | 8,601,000 | 7,693,000 | 7,991,000 | 6,609,000 |
| misc current assets | |||||||||||||||
| total current assets | 20,344,000 | 24,993,000 | 27,384,000 | 27,568,000 | 23,699,000 | 12,245,000 | 11,682,000 | 11,715,000 | 12,363,000 | 9,467,000 | 8,008,000 | 9,641,000 | 8,508,000 | 9,068,000 | 8,221,000 |
| total assets | 28,378,000 | 32,925,000 | 36,891,000 | 38,817,000 | 36,116,000 | 25,835,000 | 25,176,000 | 24,819,000 | 26,230,000 | 23,591,000 | 23,099,000 | 25,044,000 | 25,173,000 | 23,024,000 | 17,964,000 |
| Bank overdraft | |||||||||||||||
| Bank loan | |||||||||||||||
| Trade Creditors | 1,948,000 | 1,960,000 | 771,000 | 859,000 | 1,072,000 | 1,994,000 | 2,185,000 | 1,722,000 | 1,899,000 | 1,508,000 | 1,545,000 | 1,512,000 | 1,739,000 | 2,030,000 | 1,506,000 |
| Group/Directors Accounts | 123,000 | 198,000 | |||||||||||||
| other short term finances | |||||||||||||||
| hp & lease commitments | |||||||||||||||
| other current liabilities | 990,000 | 919,000 | 2,431,000 | 3,473,000 | 3,778,000 | 1,448,000 | 1,164,000 | 1,208,000 | 1,427,000 | 2,218,000 | 1,457,000 | 3,171,000 | 2,318,000 | 1,592,000 | 1,288,000 |
| total current liabilities | 2,938,000 | 2,879,000 | 3,202,000 | 4,332,000 | 4,850,000 | 3,442,000 | 3,349,000 | 2,930,000 | 3,326,000 | 3,726,000 | 3,002,000 | 4,683,000 | 4,057,000 | 3,745,000 | 2,992,000 |
| loans | |||||||||||||||
| hp & lease commitments | |||||||||||||||
| Accruals and Deferred Income | |||||||||||||||
| other liabilities | |||||||||||||||
| provisions | 4,401,000 | 4,831,000 | 3,148,000 | 2,963,000 | 6,105,000 | 2,122,000 | 2,234,000 | 2,149,000 | 2,050,000 | ||||||
| total long term liabilities | 4,401,000 | 4,831,000 | 3,148,000 | 2,963,000 | 6,105,000 | 2,122,000 | 2,234,000 | 2,149,000 | 2,050,000 | ||||||
| total liabilities | 2,938,000 | 7,280,000 | 8,033,000 | 7,480,000 | 7,813,000 | 9,547,000 | 5,471,000 | 5,164,000 | 5,475,000 | 5,776,000 | 3,002,000 | 4,683,000 | 4,057,000 | 3,745,000 | 2,992,000 |
| net assets | 25,440,000 | 25,645,000 | 28,858,000 | 31,337,000 | 28,303,000 | 16,288,000 | 19,705,000 | 19,655,000 | 20,755,000 | 17,815,000 | 20,097,000 | 20,361,000 | 21,116,000 | 19,279,000 | 14,972,000 |
| total shareholders funds | 25,440,000 | 25,645,000 | 28,858,000 | 31,337,000 | 28,303,000 | 16,288,000 | 19,705,000 | 19,655,000 | 20,755,000 | 17,815,000 | 20,097,000 | 20,361,000 | 21,116,000 | 19,279,000 | 14,972,000 |
| Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Mar 2015 | Mar 2014 | Mar 2013 | Mar 2012 | Mar 2011 | Mar 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | |||||||||||||||
| Operating Profit | |||||||||||||||
| Depreciation | 1,772,000 | 1,847,000 | 2,148,000 | 2,309,000 | 2,372,000 | 2,460,000 | 2,368,000 | 2,335,000 | 2,178,000 | 2,178,000 | 2,238,000 | 2,299,000 | 2,182,000 | 1,580,000 | 1,309,000 |
| Amortisation | |||||||||||||||
| Tax | -549,000 | ||||||||||||||
| Stock | |||||||||||||||
| Debtors | -844,000 | 1,261,000 | -215,000 | 516,000 | -1,344,000 | 1,208,000 | 1,161,000 | -1,217,000 | 1,721,000 | 950,000 | 493,000 | 225,000 | -262,000 | -535,000 | 1,612,000 |
| Creditors | -12,000 | 1,189,000 | -88,000 | -213,000 | -922,000 | -191,000 | 463,000 | -177,000 | 391,000 | -37,000 | 33,000 | -227,000 | -291,000 | 524,000 | 1,506,000 |
| Accruals and Deferred Income | 71,000 | -1,512,000 | -1,042,000 | -305,000 | 2,330,000 | 284,000 | -44,000 | -219,000 | -791,000 | 761,000 | -1,714,000 | 853,000 | 726,000 | 304,000 | 1,288,000 |
| Deferred Taxes & Provisions | -4,401,000 | -430,000 | 1,683,000 | 185,000 | -3,142,000 | 3,983,000 | -112,000 | 85,000 | 99,000 | 2,050,000 | |||||
| Cash flow from operations | |||||||||||||||
| Investing Activities | |||||||||||||||
| capital expenditure | -2,556,000 | -2,708,000 | -1,552,000 | -2,168,000 | -1,246,000 | ||||||||||
| Change in Investments | |||||||||||||||
| cash flow from investments | -2,556,000 | -2,708,000 | -1,552,000 | -2,168,000 | -1,246,000 | ||||||||||
| Financing Activities | |||||||||||||||
| Bank loans | |||||||||||||||
| Group/Directors Accounts | -123,000 | -75,000 | 198,000 | ||||||||||||
| Other Short Term Loans | |||||||||||||||
| Long term loans | |||||||||||||||
| Hire Purchase and Lease Commitments | |||||||||||||||
| other long term liabilities | |||||||||||||||
| share issue | |||||||||||||||
| interest | |||||||||||||||
| cash flow from financing | 10,000 | 12,000 | 30,000 | 10,000 | 50,000 | 20,000 | 50,000 | -590,000 | -123,000 | 348,000 | 12,695,000 | ||||
| cash and cash equivalents | |||||||||||||||
| cash | -3,805,000 | -3,652,000 | 31,000 | 3,353,000 | 12,798,000 | -645,000 | -1,194,000 | 569,000 | 1,175,000 | 509,000 | -2,126,000 | 908,000 | -298,000 | 1,382,000 | 6,609,000 |
| overdraft | |||||||||||||||
| change in cash | -3,805,000 | -3,652,000 | 31,000 | 3,353,000 | 12,798,000 | -645,000 | -1,194,000 | 569,000 | 1,175,000 | 509,000 | -2,126,000 | 908,000 | -298,000 | 1,382,000 | 6,609,000 |
beatson institute for cancer research Credit Report and Business Information
Beatson Institute For Cancer Research Competitor Analysis
Perform a competitor analysis for beatson institute for cancer research by selecting its closest rivals, whether from the PROFESSIONAL, SCIENTIFIC AND TECHNICAL ACTIVITIES sector, other large companies, companies in G61 area or any other competitors across 12 key performance metrics.
beatson institute for cancer research Ownership
BEATSON INSTITUTE FOR CANCER RESEARCH group structure
Beatson Institute For Cancer Research has 1 subsidiary company.
Ultimate parent company
1 parent
BEATSON INSTITUTE FOR CANCER RESEARCH
SC084170
1 subsidiary
beatson institute for cancer research directors
Beatson Institute For Cancer Research currently has 6 directors. The longest serving directors include Dr Iain Foulkes (Jun 2011) and Ms Rosalie Chadwick (Sep 2017).
| officer | country | age | start | end | role |
|---|---|---|---|---|---|
| Dr Iain Foulkes | England | 53 years | Jun 2011 | - | Director |
| Ms Rosalie Chadwick | United Kingdom | 47 years | Sep 2017 | - | Director |
| Professor John Iredale | England | 64 years | Sep 2018 | - | Director |
| Mr Iain McInnes | England | 60 years | Nov 2020 | - | Director |
| Mr James Kergon | United Kingdom | 49 years | Jun 2022 | - | Director |
| Mr Adrian Walsh | 57 years | Mar 2024 | - | Director |
P&L
March 2024turnover
25.7m
+6%
operating profit
-1.1m
0%
gross margin
50%
+3.59%
turnover
Turnover, or revenue, is the amount of sales generated by a company within the financial year.
Balance Sheet
March 2024net assets
25.4m
-0.01%
total assets
28.4m
-0.14%
cash
15.6m
-0.2%
net assets
Total assets minus all liabilities
beatson institute for cancer research company details
company number
SC084170
Type
Private Ltd By Guarantee w/o Share Cap
industry
72190 - Other research and experimental development on natural sciences and engineering
incorporation date
August 1983
age
42
incorporated
UK
ultimate parent company
accounts
Full Accounts
last accounts submitted
March 2024
previous names
N/A
accountant
-
auditor
PRICEWATERHOUSECOOPERS LLP
address
garscube estate, switchback road, bearsden, glasgow, G61 1BD
Bank
HSBC BANK PLC
Legal Advisor
BURNESS PAULL LLP
beatson institute for cancer research Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We did not find charges/mortgages relating to beatson institute for cancer research.
beatson institute for cancer research Capital Raised & Share Issues BETA
When a company issues new shares, e.g. to new investors following a funding round, it is required to notify Companies House within one month of making an allotment of shares.
Click to start generating capital raising & share issue transactions for BEATSON INSTITUTE FOR CANCER RESEARCH. This can take several minutes, an email will notify you when this has completed.
beatson institute for cancer research Companies House Filings - See Documents
| date | description | view/download |
|---|
